Drug firm Ipca Laboratories on Wednesday reported a 24.15 per cent rise in consolidated net profit at Rs 197.54 crore for the quarter ended on December 31, 2019, on account of robust sales.
The company had posted a net profit of Rs 159.11 crore for the corresponding period of previous fiscal, Ipca Laboratories said in a filing to the BSE.
Total income also rose to Rs 1,230.99 crore for the quarter under consideration as against Rs 1,019.48 crore in the year-ago period.
Related Stories
Ipca Laboratories has rallied sharply. Should you still buy it?
Diversified business model and capability to grow in non-US markets are positivesThe company’s board has declared an interim dividend of Rs 5 per share, Ipca Laboratories said. Shares of Ipca Laboratories were trading at Rs 1,270 per scrip on the BSE, up 1.78 per cent over previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.